FILE PHOTO: A U.S. flag flies next to the headquarters of Vertex in Boston, Massachusetts, U.S., January 28, 2019. REUTERS/Brian SnyderMore
(Reuters) – Vertex Pharmaceuticals Inc said on Wednesday its triple-combination therapy showed improvement in lung function for people with cystic fibrosis (CF) in two late-stage studies.
The combination therapy – consisting its experimental agent VX-445 and its other CF drugs Kalydeco and tezacaftor – met the main goal of improved lung function in CF patients.
CF is a rare disease that causes thick, sticky mucus to buildup in lungs, resulting in serious infections and declining organ function.
Vertex’s currently approved CF treatments,